Ligand News and Research

RSS

Research provides insight into biologic mechanisms that individual cancer cells use to metastasize to brain

New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.

4 Mar 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

New receptors act as biological postal code for treating cancer

Scientists have discovered that a polymer can provide a key to get into tumors: Prof. Prasad Shastri, Director of the Institute of Macromolecular Chemistry and core member of the cluster of excellence BIOSS Centre for Biological Signalling Studies at the University of Freiburg, and graduate students Julia Voigt and Jon Christensen have developed a new paradigm to home nanoparticles, containers that measure a few 100 nanometers in size, to endothelial cells.

11 Feb 2014

Researchers design microfluidic platform to see how cancer cells invade specific organs

Nearly 70 percent of patients with advanced breast cancer experience skeletal metastasis, in which cancer cells migrate from a primary tumor into bone - a painful development that can cause fractures and spinal compression.

7 Feb 2014

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.

3 Feb 2014

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Using a novel high-throughput screening process, scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma.

24 Jan 2014

Structural biologists advance efforts to develop new drugs targeting NMDA receptors in brain

Structural biologists at Cold Spring Harbor Laboratory (CSHL) and collaborators at Emory University have obtained important scientific results likely to advance efforts to develop new drugs targeting NMDA receptors in the brain.

23 Jan 2014

Rice University scientists create new technique to widen bottleneck for pharmaceutical, other industries

Rice University scientists have created a way to fine tune a process critical to the pharmaceutical industry that could save a lot of time and money.

23 Jan 2014

Chinese and American researchers introduce new approach to gene therapy

Resistance of tumor cells toward multiple cytostatic drugs is a serious problem in cancer treatment. In the journal Angewandte Chemie, a team of Chinese and American researchers has now introduced a new approach to gene therapy that could counter this problem: The gene that codes for resistance is “silenced” through the use of an ingenious nanocomplex.

22 Jan 2014

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

A researcher in the School of Medicine at The University of Texas Health Science Center at San Antonio received a U.S. patent Dec. 31 for his discovery that a class of compounds is protective against traumatic brain injury.

13 Jan 2014

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure.

9 Jan 2014

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

Cornell biomedical engineers have discovered a new way to destroy metastasizing cancer cells traveling through the bloodstream - lethal invaders that are linked to almost all cancer deaths - by hitching cancer-killing proteins along for a ride on life-saving white blood cells.

8 Jan 2014

CotH protein mediates fungal invasion of host cells during mucormycosis

Opportunistic infection of individuals on immunosuppressive therapy are a major problem for patient outcome, despite current prophylactic strategies.

27 Dec 2013

Research findings reveal how immune system responds to respiratory viral infections

An antibody that blocks a component of a key signaling pathway in the respiratory airways could help the immune system rid the body of the influenza virus, a new study suggests. The findings, from a team at The Research Institute at Nationwide Children's Hospital, not only offer a new approach to treating the flu, but also add new information about how the immune system responds to respiratory viral infections.

24 Dec 2013

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.

17 Dec 2013

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55th Annual Meeting of the American Society of Hematology in New Orleans.

9 Dec 2013

Ligand News and Research

Research provides insight into biologic mechanisms that individual cancer cells use to metastasize to brain

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

New receptors act as biological postal code for treating cancer

Researchers design microfluidic platform to see how cancer cells invade specific organs

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Structural biologists advance efforts to develop new drugs targeting NMDA receptors in brain

Rice University scientists create new technique to widen bottleneck for pharmaceutical, other industries

Chinese and American researchers introduce new approach to gene therapy

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

CotH protein mediates fungal invasion of host cells during mucormycosis

Research findings reveal how immune system responds to respiratory viral infections

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Ligand revises previous revenue and net income guidance for fourth quarter and full year 2013

Researchers exploit power of evolution to create new drug for use against heart disease

Cleveland Biolabs Subsidiary Awarded $4.6M Russian Contract

Study: Skin tanning gene linked to higher risk for testicular cancer in white men

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News